We are proud to annouce that Oria Bioscience has successfully closed a €2.7 million seed funding round, led by Newfund and Galion.exe, with the participation of Cenitz and Calyseed. This milestone marks a significant acceleration in our mission to make organelle accessible for therapeutic discovery worldwide.
Organelles, the tiny yet powerful compartments within cells, are increasingly recognized as key players in the origin and progression of complex diseases, including neurodegenerative disorders, cancers, cardiovascular, and rare diseases.
Yet, access to viable, functional organelles for research and development remain a bottleneck in the biotech and pharma industries.
By combining microfluidic technology with deep biological expertise, we’ve developed a gentle and scalable purification method that preserves both the integrity and functionality of organelles. Our goal is to empower scientists and biotech companies with reliable, ready-to-use organelles to accelerate the development of tomorrow’s therapeutics.
"Oria Bioscience is the first company to offer organelles as a ready-to-use bio-reagent in industrial volumes. Our aim is to make organelles accessible for the exploration of new therapeutic targets that were previously very difficult to access. Our vision is to make Oria the player and facilitator in the development of new therapies, by targeting organelles" Alexandre Santinho, CEO and co-founder of Oria
We are deeply grateful to our investors who believe in our bold vision and chose to support us at this foundational stage:
This momentum is the result of the relentless work and commitment of the Oria team, who transform our science into tanglible breakthroughs every day. What began as an idea born in the lab at LPENS just five years ago, has grown into a deep tech company with a clear vision and global ambitions.
We also owe a huge thank you to our supportive ecosystem and community: mentors, collaborators, and institutions including BiolaunchPad, BPIfrance, ENS PSL, ESPCI, HEC Challenge+, Les Deeptech, LPENS, Paris Biotech Santé, PC’UP, Région Île-de-France and WILCO, all of whom have helped Oria grow.
This funding round will accelerate our ability to:
We’re also growing the team and looking for passionate people ready to shape the future of drug discovery with us.
We’re just getting started and we’re excited to collaborate with researchers, biotech innovators, and partners worldwide who share our goal of transforming drug discovery through organelles.
Join us as we continue to grow, exciting updates ahead.
Download the full press release
